Do you want to read an article? Please log in or register.
Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis
Pulmonary Fibrosis
Related content
RECOMMENDED
Pulmonary FibrosisBronchi
Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study
★ 3
Recommended by
Dr. med. Martin Frey, Faculty Member
Lancet Respir Med
Sermet-Gaudelus I, Letierce A, Berteloot L, Bonnel AS, Chen Y, Makani P, Kelly-Aubert M, Kanoun F, Penalva L, Bouleghem N, Bihouee T, Bui S, Corvol H, Houdouin V, Mittaine M, Tatopoulos A, Weiss L, Wizla N, Kapel N, Bessou A, Tiddens HAWM, Caudri D, Reix P, Marguet C, MODUL-CF study group
doi: 10.1016/S2213-2600(25)00248-6
RECOMMENDED
Pulmonary Fibrosis
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Kharraz R, Tullis E, Sykes J, Ma X, Sandhu A, Gryz Z, Shulman Y, Tam J, Love A, Ratjen F, Rayment JH, Quon BS, Stephenson AL
doi: 10.1016/j.rmed.2026.108827
Pulmonary Fibrosis
Real-World Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis: A 24-Month Italian National Registry Study
J Clin Med
Salvatore D, Campagna G, Padoan R, Pepe A, Amato A, Salvatore M
doi: 10.3390/jcm15072699
Pulmonary HypertensionFurther Publications
Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis
Ther Adv Respir Dis
Blankenship S, Flueckiger BV, Caleb G, Bailey J, Baker E, Garcia B, Krick S
doi: 10.1177/17534666251410246
RECOMMENDED
Pulmonary Fibrosis
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Sitterlé E, Bonnel AS, Roussey-Bihouee T, Blondé A, Ribault M, Wizla N, Bresson C, Persat F, Maubon D, Leroy J, Hassani F, Benhala L, Mounier M, Znaidi S, Ferroni A, Bougnoux ME, Sermet-Gaudelus I, Mycologist and Modul-CF groups
doi: 10.1016/j.jcf.2026.02.012
Pulmonary Fibrosis
Real-world Efficacy, Safety and Heterogenicity of Efficacy of Elexacaftor-Tezacaftor-Ivacaftor in Younger Children (6-11 Years Old) with Cystic Fibrosis
Respir Med
Sheikh S, Holtzlander M, Eisner M, Gushue C, Palacios S, Mull E, Imran S, Kotha K, McCoy KS
doi: 10.1016/j.rmed.2026.109063
Pulmonary Fibrosis
Elexacaftor/tezacaftor/ivacaftor improves CFTR function to near-normal levels in children with cystic fibrosis
Eur Respir J
Berger J, Yu Y, Berges J, González A, Rossow V, Hämmerling S, Morty RE, Thee S, Stahl M, Sommerburg O, Mall MA, Graeber SY
doi: 10.1183/13993003.00422-2026
Pulmonary FibrosisFurther Publications
Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
Pediatr Pulmonol
Graziano S, Landau EC, Mitmansgrubert H, Verkleij M, Georgiopoulos AM, Borawska-Kowalczyk U, Smith BA, Bathgate CJ, Quittner AL
doi: 10.1002/ppul.71367
RECOMMENDED
Pulmonary Fibrosis
Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F
doi: 10.1016/j.jcf.2025.11.016